The Sanford Project & DiaMedica to Present Preclinical Abstract on DM-199 Treatment of Type 1 Diabetes at the 73rd Annual ADA...

The Sanford Project & DiaMedica (TSX VENTURE:DMA), announced today that their
abstract titled "Human Tissue Kallikrein (DM-199 Compound) Induces
Diabetes-Protective Immunomodulation in NOD Mouse T1D Model," has been selected
for a Late Breaking Poster Presentation at the American Diabetes Association's
(ADA) 73rd Scientific Sessions, being held on June 21-25 in Chicago, Illinois.
The poster presentation describes DM-199's mechanism of action in modulating
immunological parameters associated with developing diabetes when administered
to non-obese diabetic (NOD) mice.


The poster will be presented by Dr. Alexei Savinov, Associate Scientist at The
Sanford Project and has been assigned presentation number 56-LB in category 01-E
Clinical Therapeutics/New Technology - Non Insulin Injectable. Dr. Savinov is
scheduled to present the poster on Sunday, June 23, 2013 from 12:00 PM - 2:00
PM.


DiaMedica also announces that the Board of Directors has, subject to TSX Venture
Exchange approval, authorized amending the exercise price of the outstanding
warrants issued on May 8, 2012 in connection with DiaMedica's early exercise
incentive program from $2.50 to $1.60. All other terms of such warrants will
remain the same.


About The Sanford Project

The Sanford Project is one of the four initiatives made possible through Denny
Sanford's transformational gift to Sanford Health in 2007. From its inception,
The Sanford Project was "designed for results." Sanford Health will combine
clinical components of patient care and science into one of the most promising
and fast-moving fields of research; regenerative medicine. Their goal is to
research and cure Type 1 diabetes, all in pursuit of a healthy future for our
children. For further information please visit www.sanfordproject.org.


About DiaMedica 

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company focused on the discovery and development of novel
therapies to treat diabetes and the complications associated with diabetes.
DiaMedica's lead clinical stage compound, DM-199, is a recombinant human protein
that represents a novel approach to treating Type 1 and Type 2 diabetes.
DiaMedica is also developing a novel monoclonal antibody, DM-204 for the
treatment of Type 2 diabetes which is in preclinical development. 


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS
The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
Rick Pauls
Chairman & CEO
763-710-4455


DiaMedica Inc.
One Carlson Parkway, Suite 124
Minneapolis, MN
[e-mail]